Phaseline

Companies › Sunshine Guojian Pharmaceutical (Shanghai)

Sunshine Guojian Pharmaceutical (Shanghai): clinical trials, targets and expected readouts

8 active drug programs in 13 registered trials: 6 Phase 3, 4 Phase 2, 3 Phase 1; Immunology, Respiratory, Oncology, Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
608–Phase 3Ankylosing Spondylitis; Axial SpondyloarthritisJan 2027
610–Phase 3AsthmaFeb 2027
611–Phase 3Sinusitis; Dermatitis, Atopic; Pulmonary Disease, Chronic Obstructive (COPD)Sep 2027
SSGJ-707
bispecific antibody
–Phase 2Metastatic Colorectal CancerJun 2027
627–Phase 2Ulcerative Colitis (UC)Feb 2029
SSGJ-705
anti-PD-1 and anti-HER2 bispecific antibody
PDCD1, ERBB2Phase 1Locally Advanced, Recurrent or Metastatic MalignanciesDec 2026
SSGJ-716–Phase 1ADAug 2027
626–Phase 1Systemic Lupus Erythematosus (SLE)Aug 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06222671608Phase 2Axial SpondyloarthritisImmunologySep 2025
NCT06639295611Phase 3SinusitisRespiratoryDec 2025
NCT06390774SSGJ-705Phase 1Locally Advanced, Recurrent or Metastatic MalignanciesOncologyDec 2026
NCT07261644608Phase 3Ankylosing SpondylitisImmunologyJan 2027
NCT06323213610Phase 3AsthmaRespiratoryFeb 2027
NCT06680947610Phase 2AsthmaRespiratoryFeb 2027
NCT06493760SSGJ-707Phase 2Metastatic Colorectal CancerOncologyJun 2027
NCT07693738SSGJ-716Phase 1ADNeurologyAug 2027
NCT07767253611Phase 3Dermatitis, AtopicImmunologySep 2027
NCT07042126611Phase 3Dermatitis, AtopicImmunologySep 2027
NCT07185269626Phase 1Systemic Lupus Erythematosus (SLE)ImmunologyAug 2028
NCT07039669611Phase 3Pulmonary Disease, Chronic Obstructive (COPD)RespiratorySep 2028
NCT07507513627Phase 2Ulcerative Colitis (UC)ImmunologyFeb 2029

Targets

PDCD1 (1) ERBB2 (1)

Companies with the same targets

Beijing Biotech Shenyang Sunshine Pharmaceutical Sichuan Baili Pharmaceutical Shanghai Henlius Biotech Akeso Roche Innovent Biologics (Suzhou) Jiangsu HengRui Medicine AstraZeneca Pfizer

Companies built like this

Guangdong Hengrui Pharmaceutical Sun Pharmaceutical Industries Teva Branded Pharmaceutical Products R&D Chong Kun Dang Pharmaceutical DualityBio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.